[go: up one dir, main page]

WO2002003910A3 - Preparation antibacterienne, anticancerigene, antioxydante et immunomodulatrice et procede d'utilisation - Google Patents

Preparation antibacterienne, anticancerigene, antioxydante et immunomodulatrice et procede d'utilisation Download PDF

Info

Publication number
WO2002003910A3
WO2002003910A3 PCT/RU2001/000276 RU0100276W WO0203910A3 WO 2002003910 A3 WO2002003910 A3 WO 2002003910A3 RU 0100276 W RU0100276 W RU 0100276W WO 0203910 A3 WO0203910 A3 WO 0203910A3
Authority
WO
WIPO (PCT)
Prior art keywords
preparation
liquid
immunomoduling
anticancerogenic
antibacterial
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/RU2001/000276
Other languages
English (en)
Russian (ru)
Other versions
WO2002003910A2 (fr
Inventor
Raisa Ivanovna Yakubovskaya
Anna Vladimirovna Boyko
Elena Romanovna Nemtsova
Nadezhda Anatolievna Osipova
Tatyana Vladimirovna Sergeeva
Valery Ivanovich Chissov
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to AU2001277824A priority Critical patent/AU2001277824A1/en
Publication of WO2002003910A2 publication Critical patent/WO2002003910A2/fr
Publication of WO2002003910A3 publication Critical patent/WO2002003910A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention relève de la médecine et concerne une préparation antibactérienne, anticancérigène, antioxydante et immunomodulatrice. Selon l'invention, la préparation comprend de la lactoferrine humaine, utilisée comme principe actif, et des additifs pharmaceutiquement acceptables; elle est destinée à la préparation de médicaments ou concerne des médicaments comprenant la préparation et des excipients pharmaceutiquement acceptables tels qu'une solution pour injection intraveineuse, une solution destinée à l'instillation endocavitaire ou intravésicale, une solution destinée à l'introduction pérorale, une solution destinée au traitement des surfaces des blessures, une solution pour introduction intranasale ou se présentant comme des gouttes oculaires, une pommade, des dragées à administration pérorale, des suppositoires à administration rectale ou intravaginale et des comprimés. L'invention concerne aussi un procédé de prévention et/ou de traitement des maladies au moyen de la préparation contenant de la lactoferrine humaine. L'invention permet de créer une préparation et des médicaments à base de cette préparation ayant un coût accessible.
PCT/RU2001/000276 2000-07-13 2001-07-09 Preparation antibacterienne, anticancerigene, antioxydante et immunomodulatrice et procede d'utilisation Ceased WO2002003910A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001277824A AU2001277824A1 (en) 2000-07-13 2001-07-09 Antibacterial, antioxidant, immunomoduling and anticancerogenic preparation and method for using said preparation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2000118424 2000-07-13
RU2000118424/14A RU2165769C1 (ru) 2000-07-13 2000-07-13 Антибактериальный, антиоксидантный, иммуномодулирующий и антиканцерогенный препарат и способ его применения

Publications (2)

Publication Number Publication Date
WO2002003910A2 WO2002003910A2 (fr) 2002-01-17
WO2002003910A3 true WO2002003910A3 (fr) 2002-06-20

Family

ID=20237690

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/RU2001/000276 Ceased WO2002003910A2 (fr) 2000-07-13 2001-07-09 Preparation antibacterienne, anticancerigene, antioxydante et immunomodulatrice et procede d'utilisation

Country Status (3)

Country Link
AU (1) AU2001277824A1 (fr)
RU (1) RU2165769C1 (fr)
WO (1) WO2002003910A2 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6399570B1 (en) 1999-02-05 2002-06-04 Agennix, Inc. Antimicrobial/endotoxin neutralizing polypeptide
RU2194501C1 (ru) * 2001-06-18 2002-12-20 Государственное образовательное учреждение высшего профессионального образования Санкт-Петербургская государственная медицинская академия им. И.И. Мечникова Способ повышения резервуарной функции мочевого пузыря при хроническом цистите
AU2003239393A1 (en) 2002-05-10 2003-11-11 Agennix Incorporated Intratumorally administered lactoferrin in the treatment of malignant neoplasms and other hyperproliferative diseases
DK2298338T3 (da) 2002-09-16 2012-09-24 Agennix Inc Lactoferrin-sammensætninger og fremgangsmåder til behandling af hudsår
US7592306B2 (en) 2002-12-10 2009-09-22 Agennix, Inc. Lactoferrin as an agent in the prevention of organ transplant rejection and graft-versus-host-disease
US7323443B2 (en) 2002-12-12 2008-01-29 Agennix Inc. Lactoferrin in the reduction of pain
WO2004103285A2 (fr) 2003-05-14 2004-12-02 Agennix Incorporated Lactoferrine pour traitement du diabete sucre
CA2527904A1 (fr) 2003-06-06 2005-05-26 Agennix Incorporated Lactoferrine en tant qu'adjuvant de vaccins contre le cancer
US7183381B2 (en) 2004-10-26 2007-02-27 Agennix, Inc. Composition of lactoferrin related peptides and uses thereof
RU2360678C1 (ru) * 2008-01-30 2009-07-10 Сергей Георгиевич Павленко Способ лечения раневых поверхностей
RU2421192C1 (ru) * 2010-03-09 2011-06-20 Винера Гумаровна Нафикова Способ лечения хронического бактериального конъюнктивита
ES2627960T3 (es) 2010-11-26 2017-08-01 Evonik Röhm Gmbh Péptido derivado de lactoferrina humana para su uso como agente de enmascaramiento de antígenos
EP2481751A1 (fr) * 2011-01-26 2012-08-01 PharmaSurgics in Sweden AB Homme peptides dérivés de lactoferrine
RU2488406C1 (ru) * 2012-02-16 2013-07-27 Общество с ограниченной ответственностью "НТфарма" Фармацевтическая композиция для терапии острых токсических состояний
RU2687969C1 (ru) * 2018-03-02 2019-05-17 Федеральное государственное бюджетное учреждение науки Институт биологии гена Российской академии наук Антимикробное средство

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5543392A (en) * 1992-07-29 1996-08-06 Morinaga Milk Industry Co., Ltd. Digestive tract cell activating agent of EGF and lactoferrin
RU95102930A (ru) * 1995-02-28 1997-06-10 Московский научно-исследовательский онкологический институт им.П.А.Герцена Средство для лечения ревматоидных артритов
RU2099065C1 (ru) * 1994-09-23 1997-12-20 Московский научно-исследовательский онкологический институт им. П.А.Герцена МЗ РФ Препарат для лечения местных осложнений консервативного противоопухолевого лечения в орофарингеальной зоне и способ лечения осложнений консервативного противоопухолевого лечения в орофарингеальной зоне
WO1998044940A1 (fr) * 1997-04-10 1998-10-15 Agennix, Inc. Utilisation de la lactoferrine dans le traitement des troubles induits par allergenes
EP0955058A1 (fr) * 1997-01-09 1999-11-10 Morinaga Milk Industry Co., Ltd. Comprimes de lactoferrine

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2294018A1 (fr) * 1998-04-13 1999-10-21 New England Medical Center Hospitals, Inc. Methodes et compositions permettant d'inactiver des agents infectieux au moyen de lactoferrine et de molecules associees

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5543392A (en) * 1992-07-29 1996-08-06 Morinaga Milk Industry Co., Ltd. Digestive tract cell activating agent of EGF and lactoferrin
RU2099065C1 (ru) * 1994-09-23 1997-12-20 Московский научно-исследовательский онкологический институт им. П.А.Герцена МЗ РФ Препарат для лечения местных осложнений консервативного противоопухолевого лечения в орофарингеальной зоне и способ лечения осложнений консервативного противоопухолевого лечения в орофарингеальной зоне
RU95102930A (ru) * 1995-02-28 1997-06-10 Московский научно-исследовательский онкологический институт им.П.А.Герцена Средство для лечения ревматоидных артритов
EP0955058A1 (fr) * 1997-01-09 1999-11-10 Morinaga Milk Industry Co., Ltd. Comprimes de lactoferrine
WO1998044940A1 (fr) * 1997-04-10 1998-10-15 Agennix, Inc. Utilisation de la lactoferrine dans le traitement des troubles induits par allergenes

Also Published As

Publication number Publication date
WO2002003910A2 (fr) 2002-01-17
AU2001277824A1 (en) 2002-01-21
RU2165769C1 (ru) 2001-04-27

Similar Documents

Publication Publication Date Title
WO2002003910A3 (fr) Preparation antibacterienne, anticancerigene, antioxydante et immunomodulatrice et procede d'utilisation
WO2006039704A3 (fr) Composition pharmaceutique et methode de traitement d'une arthropathie a capsule articulaire
WO2002017881A3 (fr) Composition d'administration transdermique d'agent pharmaceutique
WO2003039436A3 (fr) Compositions pharmaceutiques contenant de l'oxybutine
IL171607A (en) Use of botulinum toxin for the treatment of sinusitis-induced headaches
WO2008062440A3 (fr) Technique de libération programmable par système flottant
EP1772767A3 (fr) Procédé pour la formation de lentilles de contact comprenant des agents thérapeutiques
BR0109875A (pt) Tratamento de doenças respiratórias
WO2005096990A3 (fr) Nouvelle modification de protheses medicales
EP1283054A4 (fr) Medicaments permettant de traiter les complications du diabete et des neuropathies et utilisation de ces medicaments
WO2005058233A3 (fr) Methodes de traitement d'une pancreatite aigue
PL362687A1 (en) Spaced drug delivery system
WO2005007072A3 (fr) Methodes et compositions pharmaceutiques pour cicatriser des lesions
CA2454976A1 (fr) Agent therapeutique contre le glaucome contenant en tant qu'ingre dient actif un compose presentant un effet inhibiteur de la kinase pi3
WO2001030380A3 (fr) Techniques et compositions destinees au traitement du keratocone au moyen d'inhibiteurs de protease
WO2001091774A3 (fr) Traitement des ulceres chroniques
CA2433833A1 (fr) Utilisation de flumazenil dans l'elaboration d'un medicament visant a traiter la dependence a l'alcool
WO2001024783A3 (fr) Utilisation de (+)-tramadol, de o-demethyltramadol ou de (+)-o-demethyltramadol, de o-desmethyle-n-mono-desmethyl-tramadol ou de (+)o-desmethyl-n-mono-desmethyl-tramadol pour traiter l'incontinence urinaire
WO2001081332A3 (fr) Composes de 2-fluorobenzenesulfonyle utilises pour le traitement d'inflammations
WO2002053090A3 (fr) Association medicamenteuse d'une biguanine (metformine) et d'arginine
WO2006050002A3 (fr) Compositions destinees a l'administration controlee de composes pharmaceutiquement actifs
WO2004103267A3 (fr) Methodes d'administration d'epothilone d
WO2008114376A1 (fr) Composition inhibitrice de la mélanogenèse
WO2005115432A3 (fr) Traitement de maladies et de troubles oculaires utilisant des compositions lantibiotiques
CA2415774A1 (fr) Procede de traitement d'arthrite ou bursite reactive

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP